Yevhenii Novodvorskyi

Yevhenii Novodvorskyi

Auto-generated profile, based on publicly available information

Yevhenii Novodvorskyi

ChemBioCenter, Kyiv National Taras Shevchenko University, Kyiv 02094, 61 Winston Churchill Street, Ukraine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2022 in Pharmacia
Verified
Journal Article
Open access
PDF file
YNYevhenii Novodvorskyi
Yevhenii Novodvorskyi
DLDmitry Lega
Dmitry Lega
IKIgor V. Komarov
Igor V. Komarov
IZIryna Zhuravel
Iryna Zhuravel
OMOleg Moskalenko
Oleg Moskalenko
SDSergii Demchenko
Sergii Demchenko
Synthesis and structure elucidation of several series of new hydrazones containing 1,2,4-triazine-5-one core and their antioxidant activity are presented. The target compounds have been synthesized via interaction of either 4-amino-6-(tert-butyl)-3-hydrazinyl-1,2,4-triazin-5(4H)-one or 6-(tert-butyl)-3-hydrazinyl-1,2,4-triazin-5(2H)-one with a wide range of compounds with a carbonyl group in moderate to high yields. Molecular structures of the synthesized compounds were confirmed by NMR, C-13 NMR, and elemental analyses. The antioxidant activity of these compounds against ascorbic acid was screened to determine their potential as promising oxidative stress suppressors. Our data showed that hydrazones derived from 4-amino-6-(tert-butyl)-3-hydrazinyl-1,2,4-triazin-5(4H)-one are the most active antioxidants among all tested compounds. Furthermore, 3 compounds of this series have been proved to be twice as active as ascorbic acid does. The conclusions are substantiated for in-depth investigations of these derivatives as promising agents for the treatment of disorders accompanied by oxidative stress.

13 January 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YNYevhenii Novodvorskyi
Yevhenii Novodvorskyi
Roman LesykRoman Lesyk
Roman Lesyk
IKIgor Komarov
Igor Komarov
DLDmitry Lega
Dmitry Lega
IZIryna Zhuravel
Iryna Zhuravel
ADAnatolii Demchenko
Anatolii Demchenko

30 September 2026 in Current Bioactive Compounds
Verified
Journal Article
Closed access
PDF file
SDSergii Demchenko
Sergii Demchenko
AMArtur Martynov
Artur Martynov
Volodymyr ZaitsevVolodymyr Zaitsev
Volodymyr Zaitsev
YNYevhenii Novodvorskyi
Yevhenii Novodvorskyi
OYOleh Yadlovskyi
Oleh Yadlovskyi
IIIvan Iurchenko
Ivan Iurchenko
Introduction: Epilepsy is a major global health burden, affecting more than 70 million people worldwide. Approximately 20-30% of patients do not achieve adequate seizure control with currently available antiseizure medications. This study investigates novel triazin-5-one derivatives as potential antiseizure agents targeting the γ-aminobutyric acid (GABA) system. The compounds were designed to interact with GABAA receptors and inhibit GABA aminotransferase (GABA-AT), using lamotrigine as a reference antiseizure drug. This dual-target strategy may support the development of more effective therapies for drug-resistant epilepsy. Materials and Methods: Eighteen 6-(4-methoxybenzyl)-3-R-4H-[1,2,4]triazin-5-one derivatives (3a–r) were synthesized and characterized by 1H and 13C NMR spectroscopy, LC-MS, and elemental analysis. Molecular docking was performed against the GABAA receptor (PDB ID: 1OHV) and GABA-AT enzyme (PDB ID: 1SF2) to estimate binding affinity. GABA-AT inhibition was evaluated in vitro, and anticonvulsant activity was assessed in mouse models at doses equimolar to 10 mg/kg lamotrigine. Results: Compounds 3o, 3f, 3r, 3g, and 3h showed the highest predicted binding affinities for the GABAA receptor, with binding-energy magnitudes exceeding 10 kcal/mol. Compound 3h (3-(2,3-dimethylphenylamino)-6-(4-methoxybenzyl)-4H-[1,2,4]triazin-5-one) exhibited the lowest IC50 value for GABA-AT inhibition (30.50 ± 0.61 μM), comparable to that of lamotrigine (32.7 ± 0.7 μM). In the animal model, compounds 3f and 3h completely suppressed clonic and recurrent clonic-tonic seizures. Docking analysis indicated that 3h forms hydrogen bonds with Arg430 and Ile426 through the triazine oxygen atom and interacts with His44 through a triazine nitrogen atom. Discussion: The anticonvulsant effects of these 1,2,4-triazine derivatives appear to depend on the substituents at positions 3 and 6 of the heterocyclic ring. Their potential dual mechanism, involving both receptor modulation and enzyme inhibition, may contribute to their neurotropic activity. Compound 3r contains a defined pharmacophore incorporating tryptamine and triazine fragments, whereas the spatial requirements underlying the activity of compound 3h remain unclear and require further structural investigation. Conclusion: The study identifies novel triazin-5-ones, specifically compounds 3h and 3f, as promising candidates for the development of new antiseizure therapies. These derivatives demonstrate potency and efficacy comparable to lamotrigine and may offer a multi-target mechanism within the GABAergic system.

4 December 2025 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
SDSergii Demchenko
Sergii Demchenko
AMArtur Martynov
Artur Martynov
YNYevhenii Novodvorskyi
Yevhenii Novodvorskyi
OYOleh Yadlovskyi
Oleh Yadlovskyi
OMOleh Moskalenko
Oleh Moskalenko
SYSergiy Yarmoluk
Sergiy Yarmoluk

9 January 2026 in ChemRxiv
Verified
Preprint
Open access
PDF file
AMArtur Martynov
Artur Martynov
SDSergii Demchenko
Sergii Demchenko
Volodymyr ZaitsevVolodymyr Zaitsev
Volodymyr Zaitsev
YNYevhenii Novodvorskyi
Yevhenii Novodvorskyi
OYOleh Yadlovskyi
Oleh Yadlovskyi
IIIvan Iurchenko
Ivan Iurchenko
Novel triazin-5-ones as potential antiseizure medicines Anxiety and related issues are major health and social concerns in developed countries, affecting 10–20% of the population. The lowest effective inhibitory concentrations for GABA-AT were observed for two compounds: 3h (30.50±0.61 µM) and 3r (44.76±0.49 µM). Their IC50 values were similar to those of lamotrigine. In vitro tests showed that compounds 3h and 3f had the lowest IC50 values for GABA-AT inhibition, at 30.50±0.61 and 44.58±0.54, respectively. The anticonvulsant activity of 6-(4-methoxybenzyl)-3-R-4H-[1,2,4] triazin-5-ones in a corral seizure model depends on modifications to substituents at positions three and six of the heterocyclic 1,2,4-triazine ring. Leading compounds, 3f (3-(4-Chlorophenylamino)-6-(4-methoxybenzyl)-4H-[1,2,4]triazin-5-one) and 3h (3-(2,3-Dimethylphenylamino)-6-(4-methoxybenzyl)-4H-[1,2,4]triazin-5-one), completely inhibit clonic and tonic-clonic seizures. Compound 3r, which contains both tryptamine and triazine fragments, has a clear pharmacophore structure. However, the spatial structure of the pharmacophore in compound 3h, with the lowest binding energy to GABAa and GABA-AT and the best performance in tests, is not yet fully understood.